ClinicalTrials.govrestricted
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine
ClinicalTrials.gov study NCT04674956. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 16
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4